Renal-Failure Anemia and Nitrosourea Therapy

Abstract

To the Editor: We read with interest the article by Harmon and his colleagues¹ in the May 24 issue of the Journal describing renal failure in children treated with methyl CCNU. We describe below a patient in whom renal failure developed after prolonged exposure to chlorozotocin, a new nitrosourea with a lesser myelosuppressive effect than BCNU, methyl CCNU or CCNU.In June, 1977, a 45-year-old woman underwent open-lung biopsy that showed bronchoalveolar-cell carcinoma. She was started on chemotherapy with chlorozotocin, 120 mg per square meter of body-surface area intravenously every six weeks from June, 1977, until December, 1978. She received . . .